BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Sezgin Göksu S, Bilal Ş, Coşkun HŞ. Hepatitis B reactivation related to everolimus. World J Hepatol 2013; 5(1): 43-45 [PMID: 23383366 DOI: 10.4254/wjh.v5.i1.43]
URL: https://www.wjgnet.com/1948-5182/full/v5/i1/43.htm
Number Citing Articles
1
Elaheh Kordzadeh-Kermani, Hossein Khalili, Iman Karimzadeh, Mohammadreza Salehi. <p>Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators</p>Infection and Drug Resistance 2020; : 513 doi: 10.2147/IDR.S233137
2
S. Yazaki, T. Yamauchi, T. Higashi. High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in JapanInternational Journal of Clinical Oncology 2020; 25(7): 1327 doi: 10.1007/s10147-020-01655-4
3
Seungtaek Lim, Jungwoo Han, Gun Min Kim, Kwang-Hyub Han, Hye Jin Choi. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenibJournal of Gastroenterology and Hepatology 2015; 30(6): 1024 doi: 10.1111/jgh.12898
4
Shoko Sonobe, Toru Arai, Yasushi Tanimoto, Chikatoshi Sugimoto, Masanori Kitaichi, Masanori Akira, Takahiko Kasai, Masaki Hirose, Yoshikazu Inoue. Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus CarrierInternal Medicine 2019; 58(4): 569 doi: 10.2169/internalmedicine.1329-18
5
Shih-Chun Chang, Chun-Yi Tsai, Keng-Hao Liu, Shang-yu Wang, Jun-Te Hsu, Ta-Sen Yeh, Chun-Nan Yeh. Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature ReviewFrontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.639967
6
Matthias S. Matter, Thomas Decaens, Jesper B. Andersen, Snorri S. Thorgeirsson. Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trendsJournal of Hepatology 2014; 60(4): 855 doi: 10.1016/j.jhep.2013.11.031
7
Annelieke E. C. A. B. Willemsen, Filip Y. De Vos, Anne Jansen, Maaike de Boer, Vivianne C. G. Tjan-Heijnen, Carla M. L. van Herpen. Diagnostic challenges of respiratory adverse events during everolimus treatmentTargeted Oncology 2014; 9(3): 287 doi: 10.1007/s11523-014-0310-4
8
Carmine D'Aniello, Marco Maruzzo, Umberto Basso. Prevention of Hepatitis B Virus Reactivation With Lamivudine in a Patient With Advanced Renal Cell Carcinoma Treated With EverolimusAmerican Journal of Therapeutics 2016; 23(1): e300 doi: 10.1097/MJT.0000000000000005
9
Claudia Bozza, Marika Cinausero, Donatella Iacono, Fabio Puglisi. Hepatitis B and cancer: A practical guide for the oncologistCritical Reviews in Oncology/Hematology 2016; 98: 137 doi: 10.1016/j.critrevonc.2015.10.017
10
Leonardo Calle García, Pilar Tajada Alegre, Victoria M. Villalta Robles, Ana Avellón Calvo, M. Astrid Rodríguez Gómez, Manuel Heras Benito, Rebeca Amo Alonso, Carmen Martín Varas, Giomar Urzola Rodríguez, M. José Fernández-Reyes Luis. Reactivation of hepatitis B virus in patient that rests dialysis after renal transplantation. How can we prevent it or anticipate it in diagnosis?Nefrología (English Edition) 2020; 40(4): 477 doi: 10.1016/j.nefroe.2019.06.008
11
Eleonora Teplinsky, Derrick Cheung, Ilan Weisberg, Ramon E. A. Jacobs, Martin Wolff, James Park, Kent Friedman, Franco Muggia, Komal Jhaveri. Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literatureBreast Cancer Research and Treatment 2013; 141(2): 167 doi: 10.1007/s10549-013-2681-0
12
Mauro Viganò, Giuseppe Serra, Giovanni Casella, Glenda Grossi, Pietro Lampertico. Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disordersExpert Opinion on Biological Therapy 2016; 16(7): 917 doi: 10.1080/14712598.2016.1177017
13
Kirsty Wai-Chung Lee, Stephen Lam Chan. Hepatotoxicity of targeted therapy for cancerExpert Opinion on Drug Metabolism & Toxicology 2016; 12(7): 789 doi: 10.1080/17425255.2016.1190831
14
Charat Thongprayoon, Wisit Kaewput, Konika Sharma, Karn Wijarnpreecha, Napat Leeaphorn, Patompong Ungprasert, Ankit Sakhuja, Franco H Cabeza Rivera, Wisit Cheungpasitporn. Outcomes of kidney transplantation in patients with hepatitis B virus infection: A systematic review and meta-analysisWorld Journal of Hepatology 2018; 10(2): 337-346 doi: 10.4254/wjh.v10.i2.337
15
Yu Shi, Min Zheng. Hepatitis B virus persistence and reactivationBMJ 2020; : m2200 doi: 10.1136/bmj.m2200
16
Isabel Ruiz-Camps, Juan Aguilar-Company. Risk of infection associated with targeted therapies for solid organ and hematological malignanciesTherapeutic Advances in Infectious Disease 2021; 8: 204993612198954 doi: 10.1177/2049936121989548
17
Leonardo Calle García, Pilar Tajada Alegre, Victoria M. Villalta Robles, Ana Avellón Calvo, M. Astrid Rodríguez Gómez, Manuel Heras Benito, Rebeca Amo Alonso, Carmen Martín Varas, Giomar Urzola Rodríguez, M. José Fernández-Reyes Luis. Reactivación silenciosa del virus de la hepatitis B en paciente que reinicia diálisis tras trasplante renal. ¿Cómo podemos prevenirlo o anticiparlo en el diagnóstico?Nefrología 2020; 40(4): 477 doi: 10.1016/j.nefro.2019.06.006
18
Mark D. Muthiah, En Ying Tan, Sin Hui Melissa Chua, Daniel Q. Y. Huang, Glenn K. Bonney, Alfred W. C. Kow, Seng Gee Lim, Yock Young Dan, Poh Seng Tan, Guan Huei Lee, Boon Leng Lim. Nucleoside analog monotherapy for prophylaxis in Hepatitis B liver transplant patients is safe and efficaciousHepatology International 2020; 14(1): 57 doi: 10.1007/s12072-019-10011-2
19
Smaragdi Marinaki, Kyriaki Kolovou, Stratigoula Sakellariou, John N Boletis, Ioanna K Delladetsima. Hepatitis B in renal transplant patientsWorld Journal of Hepatology 2017; 9(25): 1054-1063 doi: 10.4254/wjh.v9.i25.1054
20
Ivan Noreña, Mario Fernández-Ruiz, José María Aguado. Viral infections in the biologic therapy eraExpert Review of Anti-infective Therapy 2018; 16(10): 781 doi: 10.1080/14787210.2018.1521270
21
Isabel Ruiz-Camps, Juan Aguilar-Company. Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid TumorsInfectious Disease Clinics of North America 2020; 34(2): 257 doi: 10.1016/j.idc.2020.02.005
22
Zhuo Wang, Wei Jin, Hongchuan Jin, Xian Wang. mTOR in Viral Hepatitis and Hepatocellular Carcinoma: Function and TreatmentBioMed Research International 2014; 2014: 1 doi: 10.1155/2014/735672
23
Cheng-Shyong Chang, Chien-Yu Tsai, Sheng-Lei Yan. Hepatitis B reactivation in patients receiving targeted therapiesHematology 2017; 22(10): 592 doi: 10.1080/10245332.2017.1321882
24
M. Reinwald, J.T. Silva, N.J. Mueller, J. Fortún, C. Garzoni, J.W. de Fijter, M. Fernández-Ruiz, P. Grossi, J.M. Aguado. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)Clinical Microbiology and Infection 2018; 24: S53 doi: 10.1016/j.cmi.2018.02.009
25
C.S. Voican, O. Mir, P. Loulergue, M. Dhooge, C. Brezault, J. Dréanic, S. Chaussade, S. Pol, R. Coriat. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatmentAnnals of Oncology 2016; 27(12): 2172 doi: 10.1093/annonc/mdw414
26
Xinying Zhou, Yijin Wang, Herold J. Metselaar, Harry L.A. Janssen, Maikel P. Peppelenbosch, Qiuwei Pan. Rapamycin and everolimus facilitate hepatitis E virus replication: Revealing a basal defense mechanism of PI3K-PKB-mTOR pathwayJournal of Hepatology 2014; 61(4): 746 doi: 10.1016/j.jhep.2014.05.026
27
Z. Liu, L. Jiang, G. Liang, E. Song, W. Jiang, Y. Zheng, C. Gong. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis managementJournal of Viral Hepatitis 2017; 24(7): 561 doi: 10.1111/jvh.12672